DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
OMS405
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Peroxisome proliferator-activated receptor gamma agonist
OMS405
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EPETIRIMOD ESYLATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
EPETIRIMOD ESYLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
H92K6N217F
Molecule Type:
Small molecule
Molecular Formula:
C15H23N5O4S
Molecular Weight:
369.45
AlogP:
2.22
PSA:
69.62
HBD:
1.0
HBA:
#RotB:
2.0
Source:
BXT-51072
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BXT-51072
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EPB-348
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
EPB-348
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
INVAC-1, A DOUBLE STRANDED DNA PLASMID VACCINE CONSTRUCT ENCODING UBIQUITIN-HUMAN TELOMERASE REVERSE TRANSCRIPTASE (HTERT) FUSION PROTEIN
2
Enzyme
Investigational
Unknown
Unknown
Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell
Unknown
INVAC-1, A DOUBLE STRANDED DNA PLASMID VACCINE CONSTRUCT ENCODING UBIQUITIN-HUMAN TELOMERASE REVERSE TRANSCRIPTASE (HTERT) FUSION PROTEIN
×
Maximum Phase:
2
First Approval:
None
UNII:
S8GQZ8LF0D
Molecule Type:
Enzyme
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VALZIFLOCEPT
2
Protein
Investigational
Unknown
Unknown
Glomerulonephritis, IGA
Unknown
VALZIFLOCEPT
×
Maximum Phase:
2
First Approval:
None
UNII:
EA2075XV4Y
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IRX-2
2
Unknown
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Breast Neoplasms; Carcinoma, Squamous Cell; Squamous Cell Carcinoma of Head and Neck; Squamous Intraepithelial Lesions
Unknown
IRX-2
×
Maximum Phase:
2
First Approval:
None
UNII:
ZDR4QSJ43F
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OBATOCLAX
2
Small molecule
Investigational
Unknown
Unknown
Small Cell Lung Carcinoma; Leukemia, Myeloid, Acute
Unknown
OBATOCLAX
×
Maximum Phase:
2
First Approval:
None
UNII:
QN4128B52A
Molecule Type:
Small molecule
Molecular Formula:
C20H19N3O
Molecular Weight:
317.39
AlogP:
4.49
PSA:
53.17
HBD:
2.0
HBA:
#RotB:
3.0
Source:
BFH-772
2
Small molecule
Investigational
Unknown
Unknown
Rosacea
Unknown
BFH-772
×
Maximum Phase:
2
First Approval:
None
UNII:
T1IV236CVP
Molecule Type:
Small molecule
Molecular Formula:
C23H16F3N3O3
Molecular Weight:
439.39
AlogP:
5.19
PSA:
84.34
HBD:
2.0
HBA:
#RotB:
5.0
Source:
FAPI GA-68
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
FAPI GA-68
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C40H53GaN10O10
Molecular Weight:
903.65
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
M-1095
2
Unknown
Investigational
Unknown
Unknown
Psoriasis
Interleukin 17A inhibitor
M-1095
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BERUBICIN
2
Small molecule
Investigational
Unknown
Unknown
Glioblastoma
Unknown
BERUBICIN
×
Maximum Phase:
2
First Approval:
None
UNII:
6QPN83HK2M
Molecule Type:
Small molecule
Molecular Formula:
C34H35NO11
Molecular Weight:
633.65
AlogP:
2.23
PSA:
195.07
HBD:
5.0
HBA:
#RotB:
8.0
Source:
ATIPRIMOD
2
Small molecule
Investigational
Unknown
Unknown
Multiple Myeloma; Neoplasms; Carcinoma, Neuroendocrine
Unknown
ATIPRIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
MG7D3QD743
Molecule Type:
Small molecule
Molecular Formula:
C22H44N2
Molecular Weight:
336.61
AlogP:
5.57
PSA:
6.48
HBD:
0.0
HBA:
#RotB:
10.0
Source:
BVT.115959
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia
Adenosine A2a receptor agonist
BVT.115959
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NNC0114-0006
2
Unknown
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 1
Interleukin-21 binding agent
NNC0114-0006
×
Maximum Phase:
2
First Approval:
None
UNII:
L1SQ55DADE
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BELAPECTIN
2
Unknown
Investigational
Unknown
Unknown
Liver Diseases; Melanoma; Hypertension, Portal; Non-alcoholic Fatty Liver Disease; Psoriasis
Galectin-3 inhibitor
BELAPECTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
K7ODU55HT6
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MOR03087
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MOR03087
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TOSEDOSTAT
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms; Pancreatic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
Aminopeptidase inhibitor
TOSEDOSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
KZK563J2UW
Molecule Type:
Small molecule
Molecular Formula:
C21H30N2O6
Molecular Weight:
406.48
AlogP:
1.86
PSA:
124.96
HBD:
4.0
HBA:
#RotB:
9.0
Source:
PF-00446687
2
Small molecule
Investigational
Unknown
Unknown
Erectile Dysfunction; Sexual Dysfunction, Physiological
Melanocortin receptor 4 agonist
PF-00446687
×
Maximum Phase:
2
First Approval:
None
UNII:
63P236Z73I
Molecule Type:
Small molecule
Molecular Formula:
C28H36F2N2O2
Molecular Weight:
470.6
AlogP:
4.78
PSA:
43.78
HBD:
1.0
HBA:
#RotB:
3.0
Source:
ITRIGLUMIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Cholecystokinin B receptor antagonist
ITRIGLUMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
879A12466H
Molecule Type:
Small molecule
Molecular Formula:
C33H38N2O4
Molecular Weight:
526.68
AlogP:
6.84
PSA:
86.71
HBD:
2.0
HBA:
#RotB:
7.0
Source:
M5A 90Y
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
M5A 90Y
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DULIGOTUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
DULIGOTUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
8PMF8YQX2T
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DACETUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Lymphoma, Large B-Cell, Diffuse
Tumor necrosis factor receptor superfamily member 5 inhibitor
DACETUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
UT59FF4T5X
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
J591
2
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Unknown
J591
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BEDORADRINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BEDORADRINE
×
Maximum Phase:
2
First Approval:
None
UNII:
4EAR229231
Molecule Type:
Small molecule
Molecular Formula:
C24H32N2O5
Molecular Weight:
428.53
AlogP:
1.57
PSA:
102.26
HBD:
4.0
HBA:
#RotB:
9.0
Source:
CBX129801
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
CBX129801
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SAFOTIBANT
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Bradykinin B1 receptor antagonist
SAFOTIBANT
×
Maximum Phase:
2
First Approval:
None
UNII:
02HU8HWP7U
Molecule Type:
Small molecule
Molecular Formula:
C25H34N4O5S
Molecular Weight:
502.64
AlogP:
1.96
PSA:
100.54
HBD:
1.0
HBA:
#RotB:
11.0
Source:
CI-1040
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms; Pancreatic Neoplasms
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
CI-1040
×
Maximum Phase:
2
First Approval:
None
UNII:
R3K9Y00J04
Molecule Type:
Small molecule
Molecular Formula:
C17H14ClF2IN2O2
Molecular Weight:
478.66
AlogP:
5.04
PSA:
50.36
HBD:
2.0
HBA:
#RotB:
6.0
Source:
TESOFENSINE
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Diabetes Mellitus, Type 2; Obesity; Parkinson Disease; Prader-Willi Syndrome
Monoamine transporter inhibitor
TESOFENSINE
×
Maximum Phase:
2
First Approval:
None
UNII:
BLH9UKX9V1
Molecule Type:
Small molecule
Molecular Formula:
C17H23Cl2NO
Molecular Weight:
328.28
AlogP:
4.6
PSA:
12.47
HBD:
0.0
HBA:
#RotB:
4.0
Source:
ONTUXIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Melanoma; Sarcoma
Endosialin inhibitor
ONTUXIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
0M2XT000YC
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OLENDALIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Antiphospholipid Syndrome; Graft vs Host Disease
Complement C5 inhibitor
OLENDALIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
4971UQC7F3
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PEGCRISANTASPASE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
PEGCRISANTASPASE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RO6927005
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
RO6927005
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RELATLIMAB
2
Antibody
Investigational
Unknown
Unknown
Glioblastoma; Gliosarcoma; Hematologic Neoplasms; Multiple Myeloma; Colorectal Neoplasms
Lymphocyte activation gene 3 protein inhibitor
RELATLIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
AF75XOF6W3
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OXIRACETAM
2
Small molecule
Investigational
Unknown
Unknown
Attention Deficit Disorder with Hyperactivity
Unknown
OXIRACETAM
×
Maximum Phase:
2
First Approval:
None
UNII:
P7U817352G
Molecule Type:
Small molecule
Molecular Formula:
C6H10N2O3
Molecular Weight:
158.16
AlogP:
-1.94
PSA:
83.63
HBD:
2.0
HBA:
#RotB:
2.0
Source:
1
2
…
168
169
170
171
172
173
174
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA